Zambon’s Inhalable Antibiotic for Non-CF Bronchiectasis Gets Fast Track, QIDP Status from FDA
News
The U.S. Food and Drug Administration (FDA) granted Qualified Infectious Diseases Product (QIDP) and Fast Track designations to Zambon’s inhalable colistimethate sodium product to help prevent non-cystic fibrosis bronchiectasis (NCFBE) ... Read more